Trade
Trading Type
Spot
Trade crypto freely
Alpha
Points
Get promising tokens in streamlined on-chain trading
Pre-Market
Trade new tokens before they are officially listed
Margin
Magnify your profit with leverage
Convert & Block Trading
0 Fees
Trade any size with no fees and no slippage
Leveraged Tokens
Get exposure to leveraged positions simply
Futures
Futures
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
NEW
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
NEW
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
BTC Staking
HOT
Stake BTC and earn 10% APR
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
- Trending TopicsView More
15.77K Popularity
674.57K Popularity
63.1K Popularity
15.16K Popularity
508.11K Popularity
- Hot Gate FunView More
- MC:$3.7KHolders:20.02%
- MC:$3.71KHolders:20.04%
- MC:$3.66KHolders:20.09%
- MC:$3.63KHolders:20.00%
- MC:$3.68KHolders:10.80%
Fuhong Hanlin: The first patient has been dosed in the Hans joint chemotherapy first-line treatment ES-SCLC Japan bridge trial.
Jin10 data reported on June 24, the company Fuhong Hanlin announced that the first patient has been dosed in the Japanese bridge trial of Hanshuo (Surlulimumab Injection) combined with chemotherapy (Carboplatin-Etoposide) as the first-line treatment for extensive stage small cell lung cancer (ES-SCLC). This trial aims to support the market authorization application for Hanshuo in Japan. Previously, an international multi-center phase III clinical trial comparing Hanshuo or placebo combined with chemotherapy as the first-line treatment for ES-SCLC reached its primary endpoint of overall survival (OS) in December 2021.